Tech Company Financing Transactions
Sift Biosciences Funding Round
On 2/19/2026, Sift Biosciences secured $3.7 million in Seed funding from FreeFlow, LifeSpan Vision Ventures and SBI Holding.
Transaction Overview
Company Name
Announced On
2/19/2026
Transaction Type
Venture Equity
Amount
$3,700,000
Round
Seed
Investors
FreeFlow (Lead Investor) (Kevin Barrett)
LifeSpan Vision Ventures (Lead Investor) (Altar Munis)
Proceeds Purpose
The company intends to use the funds to support in vivo efficacy studies, expand its AI powered peptide discovery engine, and lead candidate selection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
733 Industrial Rd.
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Undisclosed
Website
Email Address
Overview
Borrowing Nature's Playbook To Fight Cancer and Autoimmunity; Using AI to decode nature's signals to guide the next generation of immunotherapy development. Sift is building a proprietary peptide immunotherapy platform that combines AI, metagenomics, and high-throughput T-cell screening to discover peptides that drastically amplify immune responses, unlocking targeted, effective, and safe treatment for cancers and autoimmune diseases where current therapies fall short. Our ultimate goal is to bring durable disease control to every patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yue Lou
Chief Technical Officer
Maddie Williams
Browse more venture capital transactions:
Prev: 2/19/2026: Rizon venture capital transaction
Next: 2/19/2026: Giggle venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs